Summary
Signal counts
Assets tracked: 2
Watchlist assets: 2
Registry stop assets: 0
Sponsor overview
Amsterdam UMC, location VUmc
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT03065764 | https://clinicaltrials.gov/study/NCT01175733 | https://clinicaltrials.gov/study/NCT00332163 | https://clinicaltrials.gov/study/NCT00601627 | https://clinicaltrials.gov/study/NCT01110785
Assets
Linked programs
- 89Zr-Pembrolizumab: Timeline Staleness Signal (4/5)
- Panitumumab: Results Not Found Signal (5/5)